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Objective: In whole genome and single gene analyses, genetic variation at the vascular cell adhesion
molecule-1 (VCAM-1) locus has been associated with inﬂammatory disease and stroke in sickle cell
anaemia. In the current work, we investigated the functional impact of VCAM-1 missense variants and
their effect on cellecell adhesion.
Methods and results: To determine the functional in vitro relevance of ﬁve missense VCAM-1 variants
(S318F; T384A; G413A; L555V; I716L), we generated wild type and single variant VCAM-1 forms [318F,
384A, 413A, 555V, 716L] in EA.hy926 endothelial cells. Real-time PCR, western blot and ELISA analyses
revealed signiﬁcant differences in mRNA and protein levels for VCAM-1 variants. Monocytic cell lines
THP-1 and U937 showed signiﬁcantly increased adhesion to endothelial cells overexpressing VCAM-1
forms 318F, 555V and 716L compared to those overexpressing wild type VCAM-1 (p < 0.05).
Conclusions: VCAM-1-dependent cell adhesion to endothelial cells in vitro is signiﬁcantly increased when
expressing VCAM-1 missense mutations 318F, 555V and 716L. The underlying mechanism involves
altered VCAM-1 protein levels and function. This observation may be of particular relevance for chronic
inﬂammatory pathophysiologic conditions involving cellecell adhesion such as atherosclerosis and other
proinﬂammatory conditions.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Vascular cell adhesion molecule-1 (VCAM-1, CD 106) is a gly-
cosylated cell surface protein expressed on different cell types,
including endothelial cells and ﬁbroblasts. VCAM-1 is a member ofx: þ49 251 83 35387.
enster.de, s.m.brand@uni-
er CC BY-NC-ND license.the immunoglobulin (Ig) gene superfamily with seven cell surface
Ig-like domains, a hydrophobic transmembrane domain and a short
cytoplasmic domain of 19 amino acids [1]. Human VCAM-1 is a
single copy gene at chromosome 1p32-p31, and contains nine
exons spanning w22.8 kb [2]. As a result of alternative splicing of
exon 5, two different VCAM-1 transcripts have been described [3].
Elevated expression of VCAM-1 on endothelial cells depends on the
presence of cytokines and mediates leukocyte accumulation in
inﬂamed tissues [4]. The predominant receptor for VCAM-1 is the
integrin a4b1 (very late activation antigen 4 [VLA-4]), while a4b7
and Plasmodium falciparum-infected erythrocytes also function as
VCAM-1 receptors [5e7]. Animal knock-out studies indicated a
major role of VCAM-1, compared to ICAM-1 or the selectins, in the
B. Schmitz et al. / Atherosclerosis 230 (2013) 185e190186pathogenesis of early atherosclerosis [8,9]. As genetic variation at
the VCAM-1 locus has been associated with stroke in patients
suffering sickle cell disease [10,11], we hypothesized that missense
variants of the VCAM-1 gene may inﬂuence VCAM-1 mRNA/protein
expression or protein function. To verify the presence of genetic
variants in the coding region of VCAM-1 in a European population,
we scanned 190 chromosomes from Caucasian individuals of the
Etude Cas-Temoins sur l’Infarctus du Myocarde (ECTIM) study.
Subsequent in vitro expression studies included real-time PCR,
western blot, ELISA and subsequent cellecell adhesion assays.
2. Methods
2.1. VCAM-1 missense mutations
Genomic DNA from 95 Caucasian individuals (190 alleles) of the
ECTIM Study (originally described in 1992 [12]) was prepared from
white blood cells to verify the presence of VCAM-1 missense vari-
ants in a European population. Informed written consent was ob-
tained from all study subjects and the study was approved by the
respective local ethic committees. This sample size yielded a
greater than 95% detection rate for genetic variants with a minor
allele frequency of 1% [13]. Overlapping VCAM-1 fragments were
ampliﬁed to cover 2318 bp, representing the entire coding region
and exon/intron boundaries. Ampliﬁcations were performed using
20 ng of DNA, 25 pmol of each primer and 0.2 U Taq polymerase
(GoTaq DNA-Polymerase; Promega, Mannheim, Germany). Speciﬁc
ampliﬁcation protocols for each primer pair can be obtained at our
web site (http://genecanvas.ecgene.net). Single-Strand Conforma-
tion Polymorphism (SSCP) analysis was performed as previously
described [14]. DNA presenting different migration patterns on the
polyacrylamide gels were subsequently sequenced twice using an
automated sequencing device (ABI Prism 377, Perkin Elmer, USA).
2.2. Cell culture
The human vascular endothelial cell line EA.hy926 [15] was
maintained in DMEM (SigmaeAldrich, Munich, Germany) with 10%
conditioned fetal calf serum (FCS; PAA, Cölbe, Germany), penicillin
(100 units/ml), streptomycin (100 ng/ml), and L-Glutamine
(2 mmol/ml, all SigmaeAldrich). The human monocytic cell lines
THP-1 and U937 were cultured in RPMI 1640 (SigmaeAldrich) with
10% FCS, penicillin (100 units/ml), streptomycin (100 ng/ml) and L-
Glutamine (2 mmol/ml). THP-1 cell medium was supplemented
with MEM amino acid mix (1%, SigmaeAldrich) and sodium py-
ruvate (1%, SigmaeAldrich). Different transfection reagents were
used for EA.hy926 cells (jetPEI, Polyplus-Transfection, PeqLab,
Erlangen, Germany; Nanofectin, PAA) according to manufacturers’
instructions. Cells were stimulated with TNF-a (20 ng/ml, 4 h;
SigmaeAldrich).
2.3. Generation of mutant VCAM-1 cDNA constructs
The VCAM-1 coding sequence (Acc#: NM_001078), including the
full-length 30-UTR, was subcloned into the eukaryotic expression
vector pcDNA3.1 (Invitrogen, Karlsruhe, Germany). Mutations were
introduced using the Quick-Change site-directed mutagenesis kit
(Stratagene, La Jolla, USA), generating the non-synonymous vari-
ants 318F, 384A, 413A, 555V and 716L. All vectors were sequenced
to ensure sequence accuracy and identity.
2.4. Isolation of total RNA, cDNA generation and PCR
Total RNA was extracted 24 h after transfection of cells with
VCAM-1 constructs using the RNeasy kit (Qiagen, Hilden, Germany)and up to 5 mg of total RNA was applied as template for cDNA
synthesis by SuperScript II (Invitrogen, Karlsruhe, Germany).
VCAM-1 quantitative real-time PCR was performed using Power
SYBR Green (Applied Biosystems) and primer 50-TTCCCTAGA-
GATCCAGAAATCGAG-30 (sense) and 50-CTTGCAGCTTACAGTGACA-
GAGC-30 (antisense; [16]), on an Applied Biosystems 7500 Fast
Real-Time PCR system. Samples were run in duplicates under
standard real-time PCR conditions. Relative quantiﬁcation was
calculated using the DDCt method. GAPDH (sense primer 50-
CTGCACCACCAACTGCTTAGCAC-30; antisense primer 50-GTGATGG-
CATGGACTGTGGTCATGAG-30) was used as endogenous control. The
absence of non-speciﬁc ampliﬁcationwas conﬁrmed by agarose gel
electrophoresis of PCR amplicons and generation of melting curves
using the Applied Biosystems real-time PCR system software.
2.5. Western blot analysis
Whole cell lysates were prepared 24 h after transfection with
VCAM-1 constructs using RIPA buffer containing “Complete” pro-
tease inhibitors (Roche, Mannheim, Germany). After separation by
SDS-PAGE, membranes were detected with human VCAM-1
monoclonal antibody (1:1000; Santa Cruz, Sta. Cruz, USA, sc-
13160) and anti-mouse secondary antibody (1:2000; GE Health-
care). The open source software ImageJ (http://rsbweb.nih.gov/ij/)
was used for band intensity quantiﬁcation.
2.6. VCAM-1 ELISA
Overall cellular VCAM-1 protein concentrations (RIPA extracts)
as well as extracellular soluble VCAM-1 levels from three inde-
pendent experiments were determined by ELISA (Uscn Life Science,
Houston, USA, E90547Hu) 24 h after transfection of EA.hy926 cells
with VCAM-1 expression vectors. Complete cell culture superna-
tants (2 ml) were collected, spun down and 100 ml were applied for
ELISA. Twenty mg of total cellular protein were analysed. Horse-
radish Peroxidase reaction was quantiﬁed at 450 nm following
manufacturers’ instructions on a 96-well plate reader (Inﬁnite 200
PRO NanoQuant, Tecan, Männedorf, Switzerland).
2.7. Cellecell adhesion assays
Cellecell adhesion experiments were conducted using EA.hy926
cells and THP-1 or U937 monocytes under basic conditions and
after stimulation with TNF-a. EA.hy926 cells were transiently
transfected with either VCAM-1 wild type or mutant constructs in
triplicates and adhesion experiments were performed after 24 h.
THP-1 and U937 cells were ﬂuorescence-labelled using Calcein-AM
(100 mM, 1  106 cells; R&D Systems). Endothelial cells and
monocytes were co-incubated for 30 min at 37 C. Non-adherent
cells were then removed, wells were washed twice with PBS and
cells were lysed subsequently. Spectroﬂuorometric quantiﬁcation
was performed at 492 nm (excitation) and 535 nm (emission) on a
96-well plate reader (Inﬁnite 200 PRO NanoQuant, Tecan).
2.8. Statistical analysis
GraphPad Prism Student’s t-test and one-way ANOVA was used
for statistical analysis with signiﬁcance set to p < 0.05.
3. Results
3.1. Screening for VCAM-1 variants
Screening of 95 Caucasian individuals of the ECTIM study
conﬁrmed the presence of ﬁve VCAM-1 coding variants (Fig. 1), two
cDNA
1 53 64 7 8 92
C1073T
A1270G
G1358C C1783G A2266T
Protein
LD TMligand binding sites
I II III IV V VI VII
S318F
T384A
G413A I716LL555V
Fig. 1. Schematic representation of VCAM-1. Genetic variants and exons are indicated
in the upper panel, corresponding amino acid changes in the lower panel. VCAM-1
contains a leader peptide (LD, grey), seven extracellular immunoglobulin-like do-
mains (IeVII), a transmembrane region (TM, grey) and a C-terminal tail of 18 amino
acids. Integrin binding sites are located in domains I and IV.
B. Schmitz et al. / Atherosclerosis 230 (2013) 185e190 187of which were located in exon 5 (S318F [rs3783611], T384A
[rs3783612]), one in exon 6 (G413A [rs3783613]), one in exon 7
(L555V [rs114207303]) and one in exon 9 (I716L [rs3783615]). For
subsequent molecular biological analyses, minor alleles were
introduced separately into full-length VCAM-1 cDNA including the
30-UTR, generating VCAM-1 318F, 384A, 413A, 555V and 716L.3.2. Mutant VCAM-1 transcript levels
Initially, we used the VCAM-1-negative cell line CV1 to deter-
mine potential differences in VCAM-1 mRNA expression after
introduction of the identiﬁed genetic variants, following the hy-
pothesis that missense variants may affect transcription efﬁciency,
mRNA processing and transcript stability. Using PCR ampliﬁcation
and densitometric quantiﬁcation, we did not detect any signiﬁcant
differences in VCAM-1 transcript levels in CV1 cells (Supplemental
Fig. 2). We performed additional experiments in the vascular
endothelial cell line EA.hy926, which is capable of expressing
VCAM-1. In addition, EA.hy926 cells exhibit functional anti-
inﬂammatory pathways such as peroxisome proliferator-activated
receptors [17] and miRNA-126 [18], which might inﬂuence the
expression of VCAM-1 mutants. Using real-time PCR analysis, we
detected signiﬁcant differences in VCAM-1 transcript levels with
respect to the overexpressed variant in EA.hy926 cells. With theW
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Fig. 2. VCAM-1 variants signiﬁcantly increase VCAM-1 mRNA expression in endothelial cells
1270G (384A), 1358C (413A) and 1783G (555V) were signiﬁcantly increased (p < 0.01) comp
signiﬁcant (p < 0.05) increase of VCAM-1 mRNA levels of endothelial cells overexpressin
determined via real-time PCR 24 h after transfection (n ¼ 3) and normalized to the endogeexception of 716L, all mutant constructs were associated with
signiﬁcantly elevated VCAM-1 expression levels above wild type
(p < 0.01; Fig. 2). While the VCAM-1 mRNA levels of cells
expressing 413Awas elevated up to 2-fold, VCAM-1 mRNA levels of
cells expressing 318F, 384A and 555V were elevated up to 4-fold.
Under inﬂammatory TNF-a conditions, the VCAM-1 mRNA levels of
cells expressing 318F were signiﬁcantly increased up to 6-fold
compared to wild type (p > 0.05), while cells expressing 384A
did show a trend towards strong VCAM-1 mRNA level increase
(Fig. 2). The VCAM-1mRNA levels of cells expressing 555V and 716L
were also signiﬁcantly increased under TNF-a conditions as seen at
basic conditions.
3.3. Mutant VCAM-1 protein levels
To determine potential differences in VCAM-1 protein isoform
levels and VCAM-1 glycosylation, which may be affected by the
identiﬁed VCAM-1 missense variants, western blot analyses was
used. We detected three prominent VCAM-1 protein bands of
w50 kDa,w75 kDa andw100 kDa (Fig. 3). Densitometric analysis
of VCAM-1 protein in relation to b-actin bands did not reveal any
signiﬁcant differences upon overexpression of individual VCAM-1
variants. Using the more sensitive ELISA for the determination of
total cellular VCAM-1, we observed that VCAM-1 protein levels of
cells overexpressing 716L was signiﬁcantly increased by 50%
compared to wild type (p < 0.01), while cellular VCAM-1 levels for
cells expressing all other variants remained constant (Fig. 4A). The
signiﬁcant increase of VCAM-1 in cells overexpressing 716L was
also observed under TNF-a conditions (p< 0.01; Fig. 4B). To account
for a potential effect on soluble VCAM-1, conditioned media of
transfected cells were also analysed by ELISA, but no signiﬁcant
difference was detected for any VCAM-1 variant (Fig. 4C/D).
3.4. Cellecell adhesion assays
Any of the here observed differences in VCAM-1 mRNA and
protein expression may alter VCAM-1 exposure at the cellular
surface. Moreover, amino acid changes in functionally important
VCAM-1 protein domains such as ligand binding domain 4, har-
bouring variants S318F and T384A or the transmembrane domain
I716L, may inﬂuence monocyte adhesion to endothelial cells. To
address this functional aspect, we performed cellecell adhesion
assays, using two different monocytic cell lines, THP-1 and U937,
and endothelial cells transiently transfected with VCAM-1missense
variants. This approach revealed that THP-1 adhesion was signiﬁ-
cantly enhanced in the presence of 318F, 555V and 716L comparedW
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. (A) VCAM-1 mRNA levels of endothelial cells overexpressing transcripts 1073T (318F),
ared to wild type (wt) under basic conditions (w/o). (B) TNF-a stimulation resulted in a
g transcripts 1073T (318F), 1783G (555V) and 2266T (716L). VCAM-1 expression was
nous control GAPDH. ***p < 0.001; **p < 0.01; *p < 0.05.
Fig. 3. Cellular VCAM-1 protein levels were analysed by western blot. No signiﬁcant difference was observed for VCAM-1 protein levels of endothelial cells overexpressing VCAM-1
variants in western blot analysis. The three detected VCAM-1 protein bands ofw50,w70 and 100 kDa remained constant under basic (w/o) and TNF-a conditions for all analysed
mutant VCAM-1 forms compared to wild type. VCAM-1 protein was determined via western blot 24 h after transfection. b-actin served as loading control. Western blot is
representative for experiments (n ¼ 3).
B. Schmitz et al. / Atherosclerosis 230 (2013) 185e190188to wild type (p < 0.01), yielding up to 60% more adherent mono-
cytes with respect to endothelial cells overexpressing 555V
(Fig. 5A). This effect was also observed under TNF-a conditions
except for 716L (Fig. 5B). Endothelial overexpression of 318F and
716L also affected adhesion of U937 cells signiﬁcantly (p < 0.05,
compared to wild type) while no effect of 555V was observed
(Fig. 5C). No signiﬁcant differences in U937 cell adhesion were
observed for TNF-a-treated endothelial cells (Fig. 5D). Interestingly,
enhanced extracellular VCAM-1 protein levels were also observed
in immunoﬂuorescence microscopy of endothelial cells expressing
318F and 555V when compared to wild type (Supplemental Fig. 1).
4. Discussion
In the present study, we investigated the molecular biologic
functionality of ﬁve VCAM-1 missense variants in vitro. We
observed considerable effects on VCAM-1 mRNA and proteinVC
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Fig. 4. VCAM-1 protein levels were determined by ELISA. (A) Total cellular VCAM-1 levels w
wild type (wt) under basic conditions (w/o). (B) Comparable results were observed under
soluble VCAM-1 levels in conditioned media were observed for any of the present VCAM-1
shown as standard deviation of the mean of three independent experiments. **p < 0.01.expression and detected signiﬁcantly increased adhesion of two
human monocytic cell lines to endothelial cells in the presence of
VCAM-1 forms 318F, 555V and 716L.
In contrast to other cell adhesionmolecules including ICAM-1 and
the selectins, VCAM-1 has been shown to be critical for early
atherosclerotic lesion development [8,9]. The underlyingmechanism
involves monocyte adhesion to the endothelial lining of the vessel
wall with subsequent inﬁltration of the vessel, differentiation into
macrophages, oxLDL uptake and transformation into lipid-laden
foam cells [19]. VCAM-1 missense mutations may potentially affect
this process through alteration of protein levels or protein function.
With respect to the underlying mechanisms, VCAM-1 variants
inserting in known functional domains of the protein are more likely
candidates for in vitro effects on cell adhesion. VCAM-1 contains two
Ig-like modules comprising the Ile-Asp-Ser-Pro-Leu (IDPSPL) recog-
nition sequence interacting with a4b1 [20]. The ﬁrst Ig-like module
(domain I) contains the core integrin-recognition sequence, while aVC
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Fig. 5. Adhesion of monocytes to endothelial cells is signiﬁcantly increased by VCAM-1 variants. (A) Cell adhesion of THP-1 cells under basic conditions (w/o) was signiﬁcantly
(p < 0.01) increased in the presence of 318F, 555V and 716L compared to wild type (wt). (B) Comparable results were obtained with TNF-a-treated endothelial cells (p < 0.05),
except for variant 716. (C) Cell adhesion of U937 cells under basic conditions was signiﬁcantly increased in the presence of 318F and 716L compared to wild type (wt). (D) No
signiﬁcant differences in U937 cell adhesion were observed for TNF-a-treated endothelial cells. Adhesion assays were performed 24 h after transfection of endothelial cells in
triplicates and are shown as standard deviation of the mean. Adhesion assays under basic conditions were repeated at least 4 times; adhesion assays after TNF-a stimulation at least
2 times. ***p < 0.001; **p < 0.01; *p < 0.05.
B. Schmitz et al. / Atherosclerosis 230 (2013) 185e190 189second IDPSPL site is present inmodule 4 (domain IV). Although both
modules interact with a4b1, module 1, based on the close proximity
to the cell surface, facilitates robusta4b1-mediated adhesionof blood
eosinophils. By contrast, reduced adhesion to VCAM-1 containing
onlymodules 4e7 has been reported [20], underlining the functional
difference of the two domains in cell-adhesion. Studies with leu-
kaemic cell lines have indicated that recognitionofmodule 1 and4 by
eosinophils is a complex process, which could not be explained by
a4b1 expression level and activation state alone [21]. The relevanceof
domain IV in pathophysiological processes in vivo has been high-
lighted by VCAM-1 domain 4-deﬁcient (D4D) mice, which are pro-
tected against atherosclerosis [8,9]. In the present analysis, two of the
analysedVCAM-1variants are located indomain IV, S318FandT384A.
Overexpression of the VCAM-1 form 318F in endothelial cells signif-
icantly increased adhesion of both monocytic cell lines, THP-1 and
U937, under basic conditions. The effect was also observed for THP-1
monocyteswhenendothelial cellswere stimulatedwithTNF-a. S318F
exchanges the polar amino acid serine for a more hydrophobic
phenylalanine and is qualiﬁed to be potentially damaging by the in
silico tool PolyPhen (http://genetics.bwh.harvard.edu/pph/). Notably,
overexpression of VCAM-1 form 384A, which changes a polar amino
acid to a non-polar aliphatic amino acid, didnot affect cell adhesion in
any of our experimental settings. Our results indicate that the
observed effect on increased cellecell adhesion is based on a struc-
tural change of the VCAM-1 protein due to insertion of 318F, whereas
a change in total VCAM-1 protein due to this variant seems unlikely.
Even if all analysed variants including 318F affected VCAM-1 mRNA
level, an effect that has been reported for a broad range of variants in
the transcribed region interfering with mRNA processing andturnover [22], this did not translate into detectable alterations of total
VCAM-1 protein levels.
VCAM-1 variant I716L, located within the transmembrane
domain, represents an amino acid exchange from non-polar to
basic. We observed increased VCAM-1 protein levels of up to 50% in
endothelial cells overexpressing 716L using a sensitive ELISA.
Consistently, THP-1 and U937 adhesion to endothelial cells over-
expressing 716L was signiﬁcantly increased. It is conceivable that
increased cellecell adhesion caused by this variant is based on
elevated VCAM-1 protein levels, which might originate from
altered interaction with cellular membranes and modiﬁed protein
turnovers. We also observed enhanced monocyte adhesion to
endothelial cells overexpressing 555V, which is not located in any
functional domain of the VCAM-1 protein. However, domain VI has
been reported to include two N-glycosylation sites [23] and 555V
might alter protein folding which interferes with posttranslational
glycosylation processes. Interestingly, we have observed differ-
ences between the two monocytic cell lines THP-1 and U937 with
respect to cell adhesion in presence of the three VCAM-1 forms
318F, 555v and 716L. While 318F and 716L altered adhesion of both
cell lines, 555V affected only the interaction of THP-1 monocytes
and endothelial cells. Differences in the adhesion of the two
monocytic cell lines included in our study have been reported
previously [24], pointing towards a potentially distinct mechanism
involved in the adhesion of the two cell lines.
The here described observation suggests that VCAM-1 variants
affect monocyte adhesion to endothelial cells in vitro due to distinct
mechanisms depending on the inserted variant. The effects
potentially include modiﬁcation of total VCAM-1 protein level in
B. Schmitz et al. / Atherosclerosis 230 (2013) 185e190190case of 716L and modiﬁcation of VCAM-1 protein structure and
posttranslational processes in case of 318F and 555V. Observed
alterations in VCAM-1mRNA levelsmay be based on altered folding
energies but do not directly translate into altered cell adhesion.
5. Conclusion
In conclusion, VCAM-1 variants 318F, 555V and 716L signiﬁ-
cantly increased the adhesion of monocytes to endothelial cells
in vitro. The observed effects rely on different molecular mecha-
nisms and differ between monocytic cells. This observation may be
of particular relevance for chronic inﬂammatory pathophysiologic
conditions involving cellecell adhesion such as atherosclerosis and
other proinﬂammatory conditions. The impact of the analysed
variants may point towards the distinct function of the different
VCAM-1 domains in cell type-speciﬁc adhesion. The described ef-
fects could differ between endothelial cells of different origin and
other cells and tissues, since we observed different effects in CV1
ﬁbroblasts. Further elucidation of the precise mechanisms altered
by 318F and 555V and their temporal dynamics needs to be
addressed by more extensive approaches such as surface plasmon
resonance and functional consequences should be further studied
in appropriate animal models.
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